420 with CNW — NORML Analysis Shows at Least 35,000 Studies Were Done on Cannabis in the Last 10 Years

A recent NORML analysis has revealed that over 4,000 scientific papers focusing on cannabis were published globally in 2024. This marks the fourth year that research output has reached this level.

Since 2014, over 35,000 cannabis-related studies have been released, according to NORML. These publications reflect an increasing emphasis on exploring the plant’s therapeutic benefits and the societal impacts of legalization laws.

Paul Armentano, NORML’s Deputy Director, shared insights in a blog post, noting that the past decade has seen an exponential rise in marijuana research. “Contrary to the belief that cannabis lacks sufficient scientific investigation, researchers have significantly deepened their understanding of cannabis, its active compounds, mechanisms, and its effects on users and society,” he stated. He further called on policymakers to shift their focus from uncertainties about marijuana to evidence-based discussions that reflect current knowledge.

NORML’s analysis involved a keyword search on PubMed.gov, a National Library of Medicine resource. The group reported that PubMed now lists over 49,500 scientific articles on cannabis, dating back to 1840. Interestingly, about 70% of these studies were published in the last decade, and over 90% have been added since 2002.

The research output for 2024 slightly trails the record set in 2022 when over 4,300 cannabis-related studies were published. However, the numbers still reflect a consistent upward trend compared to the previous decade, during which 32,000 studies were recorded.

Recent publications explore a variety of topics. For example, some studies highlight how cannabis legalization has reduced the rate of opioid overdose. Others discuss the plant’s ability to alleviate pain as effectively as morphine, and its role in improving the quality of life for patients with conditions like autism, epilepsy, and chronic pain.

Further research examines the effects of legalization on drug prescriptions. One study found that access to medical cannabis in Utah reduced opioid use among pain patients. Another revealed that incorporating marijuana into state prescription monitoring programs led to fewer prescriptions for narcotics.

Scientists have also delved into marijuana’s chemical components, including compounds like terpenes and minor cannabinoids. A study on cannabigerol (CBG) suggested it could help treat various conditions, including cancer and inflammation.

These studies represent just a fraction of the ongoing research into marijuana’s scientific, cultural, and legal dimensions as legalization continues to expand across the U.S., and federal reforms remain a topic of discussion in Congress. Industry actors like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) hope that this growing body of scientific literature on marijuana helps to shape future drug policy in different jurisdictions.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana Prices Gradually Reduce as Ohio’s Legal Market Grows

Data released by the Ohio Division of Cannabis Control shows that the price of marijuana has slowly been reducing since adult-use sales were launched this past summer. Dispensaries have reported slow-starts to the recreational program, indicating that vendor costs, confusion among consumers, and the state’s regulations may have contributed to this.

Under state law, licensed dispensaries aren’t allowed to sell marijuana cultivated or purchased outside the state. This has led to a decrease in vendor prices. State records also show that when adult-use sales were launched in August, the manufactured sales average for marijuana product was $31.06 while the average cost of one-tenth ounce of flower was $26.59.

As of last week, the manufactured sales average was $28.70 while the average cost of one-tenth ounce of flower was $21.72.

Terrasana’s director of marketing Nikki Stanley revealed that while they were seeing more traffic after recreational use of marijuana was launched, it still didn’t meet the expectations. Prior to the state approving Issue 2 which allowed individuals aged 21 and above to legally cultivate and use cannabis, most Ohioans were travelling to Michigan to get their marijuana fix.

Even after the recreational-use law going into effect, it appears residents in Ohio are still travelling to Michigan for marijuana. Data from Headset shows that in the last 2 years, Michigan’s marijuana market has recorded over $263 million in total sales.

With regard to sales, $178.5 million in total product sales had been recorded in Ohio as of last week.

Stanley has revealed though that dispensary marijuana prices have also been affected by potency, with higher THC content pushing prices higher. This has made products with higher potency very popular among consumers and while there’s a lot that makes a product good, new consumers seem hell bent on getting products with the highest THC.

The state’s recreational use program imposes a 10% excise tax on all adult-use purchases, with towns that have dispensaries operating in their jurisdictions receiving 36% of the funds generated.

The state has also allocated some taxes towards a substance abuse and addiction fund and a social equity fund, among others.

In addition to this, the program applies a sales tax to cannabis purchases. While the base tax rate is about 5.2% in the state, counties are allowed to impose additional sales taxes on purchases. In Green County, the total tax rate as of this year is 6.75% while in Montgomery County, it’s 7.5%.

The trend being witnessed in Ohio mirrors to a large degree what other jurisdictions in which leading firms like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) operate saw as the markets in which they are licensed had just launched.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump’s Pick for AG Triggers Hope Within the Marijuana Community

Donald Trump’s choice of Florida Representative Matt Gaetz as the next Attorney General has sparked controversy across party lines. Gaetz’s resignation from his congressional seat followed shortly after the announcement, just days before the House Ethics Committee was expected to address an ongoing investigation into allegations against him. These accusations, which Gaetz has denied, include claims of sexual misconduct and illicit drug use.

The nomination raises uncertainty about Senate approval, but it has already ignited significant interest within the cannabis industry. According to David Culver, senior vice president of public affairs at the U.S. Marijuana Council, Gaetz is among the most cannabis-friendly Republican lawmakers in Washington.

Culver noted that Trump’s decision to nominate Gaetz might indicate a serious commitment to advancing marijuana reform, a position the president-elect highlighted during his campaign.

Gaetz has consistently argued for marijuana reform, even though he rejected Amendment 3, a Florida initiative to legalize marijuana for recreational use that fell short of the necessary 60% voter approval. During his time as a state legislator, he sponsored Florida’s first bill to legalize medical cannabis.

After transitioning to Congress, he continued to push for change, supporting measures such as eliminating cannabis testing for the military. Notably, he was the only GOP co-sponsor of the MORE Act,which sought to expunge some convictions linked to marijuana and remove it from the federal restricted substances list, though the bill stalled in the Senate.

Even before Gaetz’s nomination, there was cautious optimism about how the Trump administration might handle marijuana policy. While Trump has not formally backed federal cannabis legalization, he supported Florida’s Amendment 3 and expressed interest in collaborating with Congress to provide marijuana companies access to banking systems.

He also indicated a willingness to continue efforts initiated under the Biden administration to reclassify cannabis from a Schedule I drug—considered to have no medical use—to a less restrictive Schedule III designation, grouping it with substances like anabolic steroids and ketamine.

Culver noted that Trump’s staffing decisions, including Gaetz, signal a positive outlook for federal marijuana reform. He also speculated that Gaetz could introduce updated guidelines for federal prosecutors to avoid interference in state-regulated markets.

Other marijuana advocates and industry leaders have also embraced the news. Boris Jordan, CEO of Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), shared videos of Gaetz discussing marijuana regulation where the congressman pledged to support relaxed cannabis policies. Meanwhile, groups like NORML are calling for Gaetz to spearhead efforts to delist marijuana from the CSA entirely, drawing comparisons to alcohol regulation.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Gallup Survey Finds US Bipartisan Majority Support for Cannabis Legalization Stable

Support for legalizing cannabis is showing consistent strength across the United States, according to a recent survey by Gallup. The findings highlight that a significant majority of Americans, regardless of political affiliation, continue to endorse marijuana reform.

The survey revealed a slight dip in support compared to last year’s figures, but the change falls within the margin of error and is not considered statistically significant, according to a Gallup representative. As voters head into elections where cannabis reform will appear on various state ballots, the poll indicates that 68% are in favor of legalization, while 31% remain opposed.

Breaking down the numbers by political groups, 85% of Democrats, 69% of Independents and 53% of Republicans support legalization. The survey also showed strong support across different age groups, with approval ranging from 74% among 18- to 29-year-olds to 56% among those 65 and over.

The 68% overall approval rate for cannabis legalization is a slight decrease from last year’s record-high 70%. Between 2020 and 2022, the level of support remained steady at 68%. The recent poll was conducted from October 1 to October 12 and involved 1,023 respondents, carrying a margin of error of ±4 percentage points.

In another survey released in August, Gallup found that the public perceives cannabis as less dangerous compared to substances like alcohol, vapes, and tobacco. It was also noted that more adults reported smoking cannabis compared to cigarettes.

Moreover, a 2020 poll highlighted that 70% of Americans consider smoking marijuana to be morally acceptable, a higher rate than for issues such as animal testing, gay relationships, and abortion.

In a separate set of polls conducted by YouGov in August, there was substantial support among likely voters in key swing states—Wisconsin, Michigan, and Pennsylvania—for various aspects of cannabis reform, including federal rescheduling, legalization, and access to banking services for the industry.

The strong and consistent support for cannabis reform has not gone unnoticed by presidential candidates. Both major presidential candidates—Kamala Harris and Donald Trump—have publicly supported legalization—a first in U.S. history.

Recent surveys show that a majority of marijuana users plan to vote for Kamala Harris, although around 40% have indicated they will support Trump. Harris recently stated that legalizing marijuana is a top priority on her agenda if she wins, reinforcing her previous commitment to pushing for federal legalization and ensuring legal access to cannabis.

Trump, meanwhile, has also shown support for cannabis initiatives, endorsing Florida’s ballot proposal to legalize cannabis and expressing approval for federal rescheduling and banking reform efforts.

Firms like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are probably not surprised by the data on the big fraction of Americans who support marijuana legalization since this same process played out across the border in Canada, resulting in a country-wide policy change.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Report Shows Patients in Texas Lack Access to Medical Cannabis

According to a recent report by the Texas Department of Public Safety (DPS), further actions should be taken by the state to increase accessibility to medical cannabis. The report focuses on Texas’ Compassionate Use Program (CUP), analyzing its effectiveness in providing patients across the state with reasonable access to treatment.

The findings highlight that Texas’ vast size creates specific challenges for both dispensaries and patients. According to Goodblend senior director of government relations, Jervonne Singletary, the main problem dispensaries encounter is logistics. Everything must be obtained from the pickup location, which functions as a retail location, and any unsold or uncollected items must be returned to the main hub in Austin, Texas, at the end of the day.

In the newly released 70-page DPS report, a third-party assessment was conducted to evaluate the CUP and suggest improvements. One of the most important findings in the report is the need for better access to medical cannabis for patients across Texas.

Nico Richardson, CEO of Texas Original, also underlined the necessity of tightening rules, saying, “Before thinking about expanding the number of new licenses, you need to address the regulatory framework of the current system. Overreliance on a small number of operators is unsustainable.” When CUP debuted in 2015, Texas Original was one of the first three businesses granted a license to conduct business in the state.

Richardson cautions against assuming that the issue would be resolved by merely allowing more dispensaries, particularly in underprivileged areas throughout the state. He makes the point that adding additional operators without changing the regulatory framework would make it harder for companies to survive, especially in smaller areas, and ultimately would not increase access.

Another significant issue raised in the report is the growing trend of patients turning to the hemp market for alternatives, such as delta 8 products. These products remain largely unregulated in Texas, which creates potential risks for consumers. Singletary believes this is an unintended consequence of current regulations, noting, “I don’t think the Texas legislature meant to create this situation with such easy access to hemp products.”

The unregulated hemp market has raised concerns among licensed dispensaries, as Richardson points out: “We’re regulated as if we’re handling hazardous materials like enriched plutonium, and it’s no longer reasonable.” He, along with other operators, believes that Texas needs to rethink its regulations to ensure the program can adequately serve patients.

As of now, more than 66,000 patients have enrolled in the program since its inception. However, the DPS report clarifies that this number doesn’t necessarily reflect active participants.

The data indicating that patients in Texas have limited access to medical marijuana products is likely saddening to industry actors such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) which believe that patients who want to try medical cannabis products in jurisdictions where enabling laws exist shouldn’t unduly be limited from accessing products legally.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Does Florida Cannabis Ballot Measure Stand Chance of Passing?

Former President Donald Trump recently expressed support for Amendment 3, a ballot initiative scheduled for Nov. 5, 2024, that would legalize recreational cannabis in Florida. This unexpected endorsement has added a new twist to the ongoing legalization efforts in the state.

Proponents of the measure are hoping that Trump’s backing will help sway the 15% of undecided voters to vote in favor of the legislation. With just over a month before the election, the fate of Amendment 3 is still uncertain as polls show the decision could go either way. To pass, the measure needs at least 60% of the vote; thus, every vote is crucial.

A recent Fox News poll showed 66% of voters in the state support the initiative, while another poll by Florida Atlantic University showed only 56% planned to vote yes. While polls show mixed results, the financial backing on both sides of the debate reveals a large gap.

Smart and Safe Florida, a political action committee (PAC) led by Trulieve and supporting Amendment 3, has managed to raise more than $100 million as of Sept. 20. Meanwhile, the opposition, including two anti-marijuana PACs — Keep Florida Clean and Florida Freedom Fund, aligned with Governor Ron DeSantis — has raised about $20 million.

Big donors on both sides are actively contributing to their respective causes. Trulieve has donated at least $87 million in support of the measure. On the opposing side, Ken Griffin, founder of Citadel Hedge Fund, has donated $12 million to Keep Florida Clean, with another $7 million expected.

The situation becomes even more complicated with the state’s hemp industry executives opposing the measure and pledging $5 million to fight it. This follows Governor Ron DeSantis’ veto of SB 1698 on June 7, 2024, which aimed to ban intoxicating cannabinoids derived from hemp, a move that could have severely impacted the hemp sector.

Florida’s medical marijuana market was largely dominated by multistate operators (MSOs). Verano Holdings, Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), Surterra and Ayr Wellness control 61.4% of the 603 medical cannabis dispensaries in the state, while Trulieve owns 21% of them.

Approximately 4% of Florida’s population is registered as a patient using medical marijuana, making the state’s medical cannabis market substantial.

If Amendment 3 passes, many of the current medical cannabis operators will likely transition to the recreational market. The law would take effect six months later, on May 5, 2025. However, given DeSantis’ opposition and the GOP-controlled legislature, there’s potential for political maneuvering that could delay the process well beyond that date.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — FIVE Ways to Keep Finances Healthy in Marijuana Industry

Marijuana leaders need to use sound financial techniques when operating in the cannabis sector. Given the complexities of the space, companies must devise strategies such as establishing relationships with field experts and looking for fresh revenue streams to differentiate themselves and remain competitive.

Here are five crucial financial pointers for marijuana company owners:

Focus on increasing cash flow

Maintaining a healthy cash flow is essential for any marijuana company. This entails keeping a careful eye on earnings and outlays in addition to monitoring key performance indicators such as yield per square foot for growers or average sales per customer for retailers.

A lot of new operators tend to hire too many staff members too soon or invest in pointless facility improvements. Nonetheless, companies can attain profitability more quickly and guarantee long-term financial stability by carefully controlling these costs without compromising on quality or service.

Keep accurate financial records

Clear and accurate financial records are essential for the smooth running of a cannabis business. These records not only help in regulatory compliance but are also vital for attracting investors or obtaining loans.

Hiring accountants who understand the specifics of the industry is a smart move to ensure that financial records are both detailed and correct. Regularly tracking and reporting on key performance indicators (KPIs) also provides insights that can guide decision-making and help the business adjust to changes.

Refine tax strategy

The tax regulations in the marijuana industry are complex, making it essential to work with tax professionals who are well-versed in cannabis laws. Understanding Section 280E and how it impacts your business can help reduce unnecessary tax liabilities.

Tax responsibilities can be reduced by allocating expenses to the cost of goods sold, but it’s crucial to make sure that all tax procedures adhere to legal requirements. Staying informed about regulatory changes and preparing to adapt quickly can give your businesses an edge.

Be compliant

Compliance in the cannabis sector isn’t just a legal necessity — it’s a core part of business success. A cannabis license is often the most valuable asset a business holds, so protecting it should be a top priority.

Having a knowledgeable staff that is familiar with industry rules can help a company stay ahead of compliance problems. It’s also important to stay updated on the rules in every area you operate, as they can differ greatly from one state or municipality to another.

Build solid banking relationships

Given the challenges cannabis businesses face in accessing banking services, it’s vital to establish strong relationships with financial institutions that understand the industry’s unique needs.

Look for banks that not only offer the necessary services but also provide reasonable fees. Some institutions may charge higher rates due to the nature of the business, so it’s wise to compare options.

Finding a bank that offers interest-bearing accounts can also be beneficial by adding an extra revenue stream without additional costs. Always work with trustworthy institutions to ensure transparency and minimize risks.

Each marijuana company is different, and entities such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are likely to come up with their own unique ways of making use of the strategies above as they aim to keep their finances in the best possible health.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Trump Notes Support for Cannabis Ballot Measure in Florida, Wants Public Smoking Banned

Donald Trump recently stated that he was confident Florida voters would pass the cannabis legalization initiative during the November ballot. He emphasized that since marijuana is already legal in many other states, it is unfair for someone to be prosecuted as a criminal in Florida.

In addition, Trump attacked the status quo regulations, saying they endanger public health, destroy lives and expose individuals to fentanyl-contaminated marijuana. If voters approve the measure, he encouraged lawmakers to take action by passing legislation outlawing marijuana use in public places.

Former Florida GOP chair, Senator Joe Gruters, praised Trump’s support for legalization. He said, “I am extremely proud to have President Trump join us in our effort to end the unnecessary incarcerations and arrests of adults for minor cannabis possession and to provide Floridians with the same freedom to access safe, vetted products that over half of the nation already practices.”

In line with Trump’s position, Gruters has pledged to support legislation that would outlaw marijuana use in public places should voters approve the legalization initiative.

Trump told a news reporter at a press conference in August 2024 that he was increasingly inclined to believe that people should not be criminalized for using cannabis, especially since the substance is becoming legalized nationwide. He suggested that he would soon make public his formal stance on the Florida marijuana ballot initiative.

Roger Stone, a longtime ally and Republican strategist, who resides in Florida and supports the legalization initiative, later commented that if Trump does endorse the measure, it would almost certainly lead to its approval.

Meanwhile, Representative Nancy Mace, who is sponsoring the States Reform Act to federally legalize cannabis, expressed her hope that Trump will support the Biden administration’s effort to reschedule cannabis. She also noted that many GOP lawmakers in Congress have been hesitant to embrace cannabis policy reform due to fear.

In his recent comments, Trump also criticized Vice President Kamala Harris for her record on marijuana prosecutions, claiming that she incarcerated thousands of Black individuals for cannabis-related offenses. Although this characterization of Harris’s record is somewhat exaggerated, it highlights Trump’s evolving stance on cannabis decriminalization and his willingness to leverage the issue in the political arena.

Harris has chosen Minnesota Governor Tim Walz as her running mate. Walz has been a strong advocate for marijuana reform, supporting various legislations in Congress and, as governor, signing a comprehensive marijuana legalization bill into law last year.

Marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) will be watching the presidential campaigns to see whether momentum is created for making serious changes at the federal level with regard to marijuana policy.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Scientific Review Says Medical Cannabis Shows Promise in Treating Tourette Syndrome

A recent scientific review has delved into the possible therapeutic benefits of marijuana-based medicine for treating Tourette syndrome (TS), revealing that medical cannabis might significantly help reduce the intensity of premonitory urges and tics associated with the condition.

The review’s authors examined nine studies with 401 TS patients. The findings suggest that while more research is necessary — particularly studies involving larger participant groups, standardized dosages and consistent drug formulations — marijuana-based medicine (MBM) holds promise as a treatment option for individuals with TS.

“The current study demonstrates promising and perhaps advantageous results with MBM in terms of reducing the intensity of premonitory cravings and tics,” the authors noted. They said that considering the few therapeutic choices now accessible to TS patients, these findings may be especially important.

Although there are several treatments available to lessen the frequency and intensity of tics connected to TS and improve the quality of life for patients, the authors observed a notable deficiency of strong evidence to support the efficacy of these treatments. Currently, the FDA has only approved three drugs to treat tics: aripiprazole, haloperidol and pimozide. But since there isn’t a single treatment that works for everyone, several other agents, including MBM, have been suggested as viable solutions.

The review included both cohort studies and clinical trials, and it included comparisons between measurements obtained before and after cannabis administration. The significance of the findings was evaluated using a 95% confidence interval.

The meta-analysis encompassed three trials, out of which one demonstrated a noteworthy decline in overall scores, the second showed a considerable reduction in scores and the third revealed no significant variation with the use of marijuana-based treatment.

According to the authors, their study is the first comprehensive meta-analysis and review of MBM’s efficacy in TS patients using a variety of measures. They did concede that there are questions regarding the study’s findings’ generalizability due to the very small data set and that more research is needed.

As per the Tourette Association of America, there are specific states, including Ohio, New Jersey, Missouri, Minnesota, Illinois and Arkansas, that acknowledge TS as a qualifying diagnosis for medical cannabis. In certain states, medical professionals are permitted to recommend marijuana for any disease they think would benefit from it, especially if other treatments have failed.

There is growing momentum in the United States to loosen regulations surrounding medical marijuana research. Even though reclassification by itself wouldn’t make recreational or medical cannabis markets lawful in any state, it might have several effects on government workers, taxation, research and other sectors.

The full benefits of the medical cannabis products from the thousands of licensed marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are unlikely to be fully known in the years to come until extensive research is done to document how different groups of patients respond when they consume these products.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Legalizing Medical Cannabis in North Carolina Still Faces Huge Hurdles

For the third year in a row, the senate of North Carolina approved the Compassionate Care Act. The measure aims to allow the sale of marijuana and marijuana-infused products to patients who qualify under a set of strict conditions, utilizing a regulated medical marijuana system. Despite this progress, the legislation is presently stuck in the house.

Adding to the complexity, a recent decision by the Supreme Court has influenced the discussion around reclassifying marijuana as a Schedule 3 drug. Changing its classification from Schedule 1 to Schedule 3 would formally recognize its medical use, representing a small yet significant step toward legalization in North Carolina.

Earlier this year, the Eastern Band of Cherokee Indians launched the state’s first dispensary for medical cannabis, sparking renewed hope among Charlotte’s hemp entrepreneurs for the broader acceptance of medical cannabis. However, the dispensary operates outside of state law because of the tribe’s sovereign status.

According to Natacha Andrews, National Association of Black Cannabis Lawyers CEO, a majority of North Carolinians support the legalization of medical cannabis, despite a “stigma wall” that some legislators and residents still hide behind. Andrews pointed out that more than 80% of respondents in polls have expressed support for medical cannabis. However, some individuals self-exclude from the conversation due to long-standing beliefs instilled by their upbringing, religious teachings or societal norms that associate cannabis with negative connotations.

The proposed legislation is designed to aid individuals dealing with severe medical conditions such as PTSD, cancer and epilepsy. It has garnered bipartisan backing in the state legislature, including support from Republican Senator Bill Rabon, who has openly credited cannabis with aiding his recovery from colon cancer.

Conversely, Senator Jim Burgin, another Republican, argued that cannabis is not a recognized medicine, pointing out its lack of FDA approval and its current status as a controlled substance. Even if marijuana were to receive federal approval, Burgin stated that he would advocate for restricted forms of administration, such as suppositories, drops or nebulizers, as alternatives to smoking.

Financial projections suggest that legalizing medical marijuana in North Carolina could generate more than $15 million in the first year through application fees and a 10% tax on gross sales. However, Burgin contended that financial gain should not be the driving force behind legalization, especially if the primary goal is to address health issues and support those suffering from conditions such as PTSD.

Andrews believes that the question isn’t if marijuana will become legal in North Carolina, but when. She urges residents and businesses to prepare for the inevitable legalization as societal perceptions and global attitudes toward cannabis continue to shift.

Currently, the bill remains stuck in the house, with Speaker Tim Moore stating that they need 37 Republican votes to bring the bill to the floor. They have yet to secure the necessary support. Marijuana industry players, including major enterprises such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF), will be hoping that the legislators in the state soon find a way to give patients an option of trying medical marijuana as an alternative or complement to the conventional medications they take to combat the diseases afflicting them.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com